<DOC>
	<DOC>NCT01461044</DOC>
	<brief_summary>This observational study will evaluate the safety and efficacy of triple negative or HR+ patients with HER2-metastatic or locally advanced breast cancer treated with Avastin (bevacizumab) as first line therapy for at least 12 months and without disease progression for at least 12 months. Data will be collected retrospectively (from the diagnosis to the inclusion in the study) and for 18 months from study start.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age HER2metastatic breast cancer or locally advanced breast cancer Patients with Avastin as first line therapy administered for at least 12 months Patients without disease progression after the beginning of Avastin treatment for at least 12 months Patients not willing to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>